<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346151</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN023ST</org_study_id>
    <nct_id>NCT00346151</nct_id>
  </id_info>
  <brief_title>Belatacept to Prevent Organ Rejection in Kidney Transplant Patients</brief_title>
  <acronym>BESTT</acronym>
  <official_title>The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Belatacept is an experimental medication shown in clinical trials to have immune system
      suppression properties in people who have had renal (e.g., kidney) transplants. This study
      will determine whether a combination of anti-rejection drugs, including belatacept, can
      prevent the rejection of a first-time, non-human leukocyte antigen (HLA) identical renal
      transplant and allow patients to be safely withdrawn from anti-rejection therapy one year
      post-transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drugs that suppress the immune system have contributed to increased success of
      transplantation; however, to prevent organ rejection, transplant recipients need to take
      immunosuppressive drugs for the rest of their lives. These drugs make patients more
      susceptible to infection and certain kinds of cancer. Belatacept is an experimental
      medication that specifically targets immune reactions against transplanted organs and has
      been shown to be effective in preventing kidney transplant rejection in previous clinical
      trials. Both thymoglobulin, an antibody, and sirolimus, an anti-rejection drug, prevent
      rejection by lowering the response of the immune system to the transplanted organ. This study
      will evaluate whether belatacept, along with thymoglobulin and sirolimus, is safe in kidney
      transplant patients. The study will also evaluate this regimen's potential to allow tapering
      and eventual discontinuation of all immunosuppressive drugs.

      This study will last up to 4 years. At the time of transplant, participants will begin an
      immunosuppressive treatment regimen consisting of thymoglobulin, sirolimus, and belatacept.
      Participants will receive infusions of thymoglobulin on days 1 through 4, and a combination
      of oral sirolimus (daily) and belatacept infusions at day 5, then weeks 2, 4, 8, and monthly
      for at least 2 years. Dose reduction of belatacept will occur at 12 weeks post-transplant. At
      Year 2, eligible participants may choose to begin drug withdrawal or continue study therapy
      through the end of the study. Study visits will occur weekly for the first two months, then
      monthly. These visits will include belatacept treatment, general medical assessments, blood
      and urine collection, and other assessments to determine overall health of the recipient's
      immune system and kidney transplant and to better understand the way the immune system works
      in the acceptance or rejection of organ transplants.

      *** IMPORTANT NOTICE: *** The National Institute of Allergy and Infectious Diseases and the
      Immune Tolerance Network do not recommend the discontinuation of immunosuppressive therapy
      for recipients of cell, organ, or tissue transplants outside of physician-directed,
      controlled clinical studies. Discontinuation of prescribed immunosuppressive therapy can
      result in serious health consequences and should only be performed in certain rare
      circumstances, upon the recommendation and with the guidance of your health care provider.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopping rule-acute rejection threshold-was met based on local biopsy results
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Rejection at 6-Months</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>Cumulative incidence of acute rejection[1] at 6 months post-transplant based on local pathology biopsy reads
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant Survival at 12 Months Post-Transplant</measure>
    <time_frame>12 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Rejection at 12-Months</measure>
    <time_frame>12 months post-transplant</time_frame>
    <description>Incidence of acute rejection[1] at 12 months post-transplant
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance Induction</measure>
    <time_frame>48 months</time_frame>
    <description>Time from transplantation to initiation of sirolimus withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function as Measured by Glomerular Filtration Rate (GFR) at 24 Weeks</measure>
    <time_frame>24 weeks post-transplant</time_frame>
    <description>GFR utilizing clearance of iothalamate.
GFR is an index of level of kidney function. A higher value means better kidney function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Survival at 12 Months Post-transplant</measure>
    <time_frame>12 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Transplant to Acute Rejection</measure>
    <time_frame>Transplantation until rejection occurs (participants followed up to four years post-transplantation)</time_frame>
    <description>Time (days) from transplant to occurrence of acute rejection[1]
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Requiring Antilymphocyte Therapy for Acute Rejection</measure>
    <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
    <description>Proportion of participants who experienced acute rejection[1] requiring antilymphocyte therapy
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713-723, 1999</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Post-transplant Infections</measure>
    <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
    <description>Proportion of participants who experienced infections post-transplant. Participants were checked for any type of opportunistic infection at all study visits post-transplantation (up to 4 years post-transplantation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Wound Complications</measure>
    <time_frame>Start of study to end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Malignancies</measure>
    <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With a Sirolimus Associated Adverse Event</measure>
    <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Chronic Allograft Nephropathy</measure>
    <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Delayed Graft Function</measure>
    <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Post-transplant Diabetes Mellitus</measure>
    <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Belatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks</description>
    <arm_group_label>Belatacept</arm_group_label>
    <other_name>LEA29Y</other_name>
    <other_name>Nulojix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year</description>
    <arm_group_label>Belatacept</arm_group_label>
    <other_name>Rapamycin</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thymocyte globulin</intervention_name>
    <description>1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.</description>
    <arm_group_label>Belatacept</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>anti-thymocyte immunoglobulin</other_name>
    <other_name>Thymoglobulin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4</description>
    <arm_group_label>Belatacept</arm_group_label>
    <other_name>Medrol</other_name>
    <other_name>glucocorticoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving first renal (e.g., kidney) transplant

          -  Transplant is from a non-HLA-identical living donor

          -  Willing to use acceptable forms of contraception

        Exclusion Criteria:

          -  Positive for anti-human globulin (AHG) or T-cell cross-match with the donor

          -  Receiving multiple-organ transplant

          -  History of cancer within the 5 years prior to study entry. Patients who have certain
             nonmelanoma skin cancers are not excluded

          -  Human immunodeficiency virus (HIV) infected

          -  Hepatitis B (HBV) or C (HCV) virus infected

          -  Other active infections

          -  Active tuberculosis (TB) infection within the 3 years prior to study entry

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Vincenti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Larsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT) website</description>
  </link>
  <link>
    <url>http://www.immunetolerance.org</url>
    <description>Immune Tolerance Network (ITN) website</description>
  </link>
  <reference>
    <citation>Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005 Aug 25;353(8):770-81.</citation>
    <PMID>16120857</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <results_first_submitted>June 8, 2011</results_first_submitted>
  <results_first_submitted_qc>September 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2011</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal transplantation</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>renal allograft recipient</keyword>
  <keyword>anti-rejection drugs</keyword>
  <keyword>immunosuppression protocol</keyword>
  <keyword>immunosuppression withdrawal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data access is provided to the public in Participant level data and additional relevant materials are available to the public in : 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>SDY674</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY674</doc_url>
      <doc_comment>ImmPort study identifier is SDY674</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SDY674</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY674</doc_url>
      <doc_comment>ImmPort study identifier is SDY674. The study protocol is available in the Design tab section.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SDY674</doc_id>
      <doc_type>Study summary, -design, -synopsis,- medications, -demographics, -lab tests, -files</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY674</doc_url>
      <doc_comment>ImmPort study identifier is SDY674</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ITN023ST</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN023STPUBLIC/Study%20Data/begin.view?</doc_url>
      <doc_comment>TrialShare is a clinical trials research portal developed by the Immune Tolerance Network (ITN) that makes data from the consortium's clinical trials publicly available.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ITN023ST</doc_id>
      <doc_type>Protocol synopsis, -data and reports, -specimens availability</doc_type>
      <doc_url>http://www.itntrialshare.org/project/Studies/ITN023STPUBLIC/Study%20Data/begin.view?</doc_url>
      <doc_comment>TrialShare is a clinical trials research portal developed by the Immune Tolerance Network (ITN) that makes data from the consortium's clinical trials publicly available.</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Two centers in the United States enrolled five recipients of non-human leukocyte antigen (HLA)-identical living-donor-related renal transplants between January 2007 and January 2009.</recruitment_details>
      <pre_assignment_details>At a screening visit, participants underwent procedures to establish inclusion/exclusion criteria and sign the informed consent form.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Belatacept</title>
          <description>Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Immunosuppression Withdrawal</title>
          <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Rejection at 6-Months</title>
        <description>Cumulative incidence of acute rejection[1] at 6 months post-transplant based on local pathology biopsy reads
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713–723, 1999</description>
        <time_frame>6 months post-transplant</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Rejection at 6-Months</title>
          <description>Cumulative incidence of acute rejection[1] at 6 months post-transplant based on local pathology biopsy reads
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713–723, 1999</description>
          <population>Intent to Treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion of participant's cumulative incidence of acute rejection at 24 weeks with 95% exact binomial confidence interval. Local biopsy reads were used in determining primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>60</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>15</ci_lower_limit>
            <ci_upper_limit>95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Survival at 12 Months Post-Transplant</title>
        <time_frame>12 months post-transplant</time_frame>
        <population>Intent to Treat Sample participants not terminating prior to 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Survival at 12 Months Post-Transplant</title>
          <population>Intent to Treat Sample participants not terminating prior to 12 months.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>40</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Rejection at 12-Months</title>
        <description>Incidence of acute rejection[1] at 12 months post-transplant
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713–723, 1999</description>
        <time_frame>12 months post-transplant</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Rejection at 12-Months</title>
          <description>Incidence of acute rejection[1] at 12 months post-transplant
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713–723, 1999</description>
          <population>Intent to Treat Sample</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence rate</param_type>
            <param_value>80</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>28</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerance Induction</title>
        <description>Time from transplantation to initiation of sirolimus withdrawal.</description>
        <time_frame>48 months</time_frame>
        <population>Intent to treat sample that initiated sirolimus withdrawal</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerance Induction</title>
          <description>Time from transplantation to initiation of sirolimus withdrawal.</description>
          <population>Intent to treat sample that initiated sirolimus withdrawal</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function as Measured by Glomerular Filtration Rate (GFR) at 24 Weeks</title>
        <description>GFR utilizing clearance of iothalamate.
GFR is an index of level of kidney function. A higher value means better kidney function.</description>
        <time_frame>24 weeks post-transplant</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function as Measured by Glomerular Filtration Rate (GFR) at 24 Weeks</title>
          <description>GFR utilizing clearance of iothalamate.
GFR is an index of level of kidney function. A higher value means better kidney function.</description>
          <population>Intent to Treat Sample</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Survival at 12 Months Post-transplant</title>
        <time_frame>12 months post-transplant</time_frame>
        <population>Intent to treat sample participants not terminating prior to 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Survival at 12 Months Post-transplant</title>
          <population>Intent to treat sample participants not terminating prior to 12 months</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>40</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Transplant to Acute Rejection</title>
        <description>Time (days) from transplant to occurrence of acute rejection[1]
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713–723, 1999</description>
        <time_frame>Transplantation until rejection occurs (participants followed up to four years post-transplantation)</time_frame>
        <population>Intent to treat sample participants with rejection</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Transplant to Acute Rejection</title>
          <description>Time (days) from transplant to occurrence of acute rejection[1]
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713–723, 1999</description>
          <population>Intent to treat sample participants with rejection</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="95.4" lower_limit="1" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Requiring Antilymphocyte Therapy for Acute Rejection</title>
        <description>Proportion of participants who experienced acute rejection[1] requiring antilymphocyte therapy
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713–723, 1999</description>
        <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Requiring Antilymphocyte Therapy for Acute Rejection</title>
          <description>Proportion of participants who experienced acute rejection[1] requiring antilymphocyte therapy
Diagnosis of acute rejection was made by renal (kidney) biopsy using the Banff 97 criteria. The Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Acute rejection is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater[2]
Reference: Racusen LC, Solez K, Colvin RB et al,The Banff 97 working classification of renal allograft pathology. Kidney Int,55: 713–723, 1999</description>
          <population>Intent to Treat Sample</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>52.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Post-transplant Infections</title>
        <description>Proportion of participants who experienced infections post-transplant. Participants were checked for any type of opportunistic infection at all study visits post-transplantation (up to 4 years post-transplantation)</description>
        <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Post-transplant Infections</title>
          <description>Proportion of participants who experienced infections post-transplant. Participants were checked for any type of opportunistic infection at all study visits post-transplantation (up to 4 years post-transplantation)</description>
          <population>Intent to Treat Sample</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>80</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>28</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Wound Complications</title>
        <time_frame>Start of study to end of study</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Wound Complications</title>
          <population>Intent to Treat Sample</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>52.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Malignancies</title>
        <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Malignancies</title>
          <population>Intent to Treat Sample</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>52.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With a Sirolimus Associated Adverse Event</title>
        <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With a Sirolimus Associated Adverse Event</title>
          <population>Intent to Treat Sample</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>47.8</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Chronic Allograft Nephropathy</title>
        <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Chronic Allograft Nephropathy</title>
          <population>Intent to Treat Sample</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>52.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Delayed Graft Function</title>
        <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Delayed Graft Function</title>
          <population>Intent to Treat Sample</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>52.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Post-transplant Diabetes Mellitus</title>
        <time_frame>Participants followed from transplantation until completion of study (up to four years post-transplantation)</time_frame>
        <population>Intent to Treat Sample</population>
        <group_list>
          <group group_id="O1">
            <title>Immunosuppression Withdrawal</title>
            <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Post-transplant Diabetes Mellitus</title>
          <population>Intent to Treat Sample</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Proportion with 95% exact binomial confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence Rate</param_type>
            <param_value>20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>71.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Immunosuppression Withdrawal</title>
          <description>Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Epstein-Barr viraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Graft dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was stopped early due to meeting an acute rejection threshold of three acute rejections based on local pathology reads in the first five participants enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director, Clinical Research Program</name_or_title>
      <organization>DAIT/NIAID</organization>
      <phone>301-594-7669</phone>
      <email>DAITClinicalTrialsGov@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

